WO2005053609A3 - Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante - Google Patents

Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante Download PDF

Info

Publication number
WO2005053609A3
WO2005053609A3 PCT/US2004/039220 US2004039220W WO2005053609A3 WO 2005053609 A3 WO2005053609 A3 WO 2005053609A3 US 2004039220 W US2004039220 W US 2004039220W WO 2005053609 A3 WO2005053609 A3 WO 2005053609A3
Authority
WO
WIPO (PCT)
Prior art keywords
nad
methods
deacetylase inhibitors
dependent deacetylase
dependent
Prior art date
Application number
PCT/US2004/039220
Other languages
English (en)
Other versions
WO2005053609A2 (fr
Inventor
Jie Zhang
Weizheng Xu
Original Assignee
Guilford Pharm Inc
Jie Zhang
Weizheng Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc, Jie Zhang, Weizheng Xu filed Critical Guilford Pharm Inc
Publication of WO2005053609A2 publication Critical patent/WO2005053609A2/fr
Publication of WO2005053609A3 publication Critical patent/WO2005053609A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom

Abstract

La présente invention concerne des méthodes de traitement du cancer, de troubles cardiovasculaires et de troubles neurologiques à l'aide d'inhibiteurs de désacétylase NAD+ dépendante.
PCT/US2004/039220 2003-11-26 2004-11-23 Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante WO2005053609A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52530303P 2003-11-26 2003-11-26
US60/525,303 2003-11-26

Publications (2)

Publication Number Publication Date
WO2005053609A2 WO2005053609A2 (fr) 2005-06-16
WO2005053609A3 true WO2005053609A3 (fr) 2005-09-01

Family

ID=34652323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039220 WO2005053609A2 (fr) 2003-11-26 2004-11-23 Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante

Country Status (1)

Country Link
WO (1) WO2005053609A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
GB0816269D0 (en) 2008-09-05 2008-10-15 Univ Ramot Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
WO2011137320A2 (fr) * 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de petites molécules de l'activité de l'enzyme de déubiquination usp1
CN103124563B (zh) * 2010-08-04 2016-08-10 佩尔菲丘尔制药有限公司 用于前列腺癌治疗的联合治疗
US9861596B2 (en) 2012-11-09 2018-01-09 Musc Foundation For Research Development Compositions and methods for treating neurological diseases or injury
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
KR101876750B1 (ko) * 2016-07-26 2018-07-11 한밭대학교 산학협력단 신규한 2-아민 치환 1,4-나프토퀴논 화합물 및 이를 포함하는 암의 예방 또는 치료용 약제학적 조성물
JP2021533115A (ja) * 2018-07-29 2021-12-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメントMusc Foundation For Research Development 神経疾患またはミトコンドリア疾患の処置のための化合物
CN113368087A (zh) * 2020-03-10 2021-09-10 复旦大学附属华山医院 胡桃醌其衍生物及其在制备化疗脑肿瘤的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
WO2003007933A1 (fr) * 2001-07-16 2003-01-30 The University Court Of The University Of Aberdeen Derives de napthoquinone en tant qu'inhibiteurs de l'agregation des tau pour le traitement de la maladie d'alzheimer et des troubles de neurodegenerescence associes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
WO2003007933A1 (fr) * 2001-07-16 2003-01-30 The University Court Of The University Of Aberdeen Derives de napthoquinone en tant qu'inhibiteurs de l'agregation des tau pour le traitement de la maladie d'alzheimer et des troubles de neurodegenerescence associes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HODNETT E. ET AL: "Subtituted 1,4-Naphthoquinones vs. the Ascitic Sarcoma 180 of Mice.", J.MED.CHEM., vol. 23, no. 4, 1983, pages 570 - 574, XP002988938 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
WO2005053609A2 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005053609A3 (fr) Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante
WO2006055871A3 (fr) Traitement de la sclerose en plaques
WO2006023649A3 (fr) Traitement de la sclerose en plaques grave
WO2004009776A3 (fr) Traitement de troubles en relation avec le tnf$g(a)
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2006044825A3 (fr) Inhibiteurs de la kinesine mitotique et methodes d'utilisation desdits inhibiteurs
WO2004066987A3 (fr) Methodes destinees a traiter les troubles du tractus gastro-intestinal au moyen de modulateurs du canal sodique
WO2007073505A3 (fr) Méthodes et compositions de traitement de la douleur
WO2005103041A3 (fr) Traitement des troubles du systeme nerveux central au moyen de modulateurs cibles du snc
WO2005030791A3 (fr) Inhibiteurs du canal potassique d'isoquinolinone
WO2004048551A3 (fr) Cible destinee a la therapie d'un trouble cognitif
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2005074375A3 (fr) Inhibiteurs de l'heparanase et utilisations
WO2005044093A3 (fr) Compositions de delta-9-thc et methodes de traitement de symptomes lies la sclerose en plaques
WO2005007141A3 (fr) Inhibiteurs de l'ubiquitine ligase et methodes associees
WO2005046578A3 (fr) Inhibiteurs du canal potassique isoquinolinone
WO2005117939A3 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
WO2003088748A8 (fr) Utilisation d'heme-oxygenase-1 et produits de degradation d'heme
WO2007112121A3 (fr) Composés à base de tétracyline et procédés de traitement
WO2004052236A3 (fr) Methodes et compositions de traitement de l'otite moyenne
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
WO2004058158A3 (fr) Traitement du cancer metastatique avec la sous-unite de la toxine de shiga
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
WO2005013911A3 (fr) Usages protecteurs et therapeutiques de tocotrienols
WO2006015191A3 (fr) Analogues de lonidamine multicycliques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase